Business Wire

IWBI Launches WELL v2™

Jaa

Launched today worldwide and celebrated with fanfare in New York, Beijing, London and Sydney, the International WELL Building Institute™ (IWBI™) unveiled the WELL v2™ pilot, the next version of its pioneering WELL Building Standard™, the first rating system to focus exclusively on the impacts of buildings on human health and wellness.

This second iteration includes a full suite of enhancements that advance IWBI’s global aim to build a healthier future for all. WELL v2 is informed by key lessons learned from the nearly 1,000 projects that are registered or certified in 34 countries across the world. Users can register for WELL v2 starting today.

“Since our launch in 2014, we’ve learned a lot from the thousands of WELL users, practitioners and researchers who have embraced WELL as a tool for making buildings mechanisms to deliver health and wellness benefits for all,” said IWBI Chief Product Officer Rachel Gutter. “WELL v2 is our effort to consolidate the latest knowledge, leading research, new technology and advanced building practice to extend the benefits of WELL buildings to more people in more places.”

A truly global rating system, the intent behind WELL v2 is to empower project teams to pursue the interventions that matter most to their project and their community without sacrificing WELL’s comprehensive and evidence-based approach and commitment to performance verification. Refinements and enhancements to the rating system include:

  • A new feature set with fewer preconditions and weighted optimizations.
  • A consolidation of multiple pilots into one WELL, and improvements to the “All Projects In” approach introduced last year.
  • New pathways to achieve intents, with a laser focus on feasibility for existing buildings and commercial interiors.
  • An optional early phase review for projects wishing to earn a WELL D&O™ designation that affirms and celebrates progress toward WELL Certification.
  • A new approach to performance verification allowing projects to contract local providers.
  • A commitment to equity through market- and sector-specific pricing, a focus on localization and the introduction of a dynamic scorecard.
  • A comprehensive and significant adjustment to pricing, including a new subscription option.

“The IWBI team has worked tirelessly to aggregate the expert contributions of our worldwide community of users, researchers and thought leaders whose hands-on engagement with WELL v2 is evident throughout,” said IWBI CEO and Chairman Rick Fedrizzi. “The result is a rating system that’s simpler, clearer, focused on the aspects that have the greatest impact, and designed for improved return across every metric. I’m especially excited about the significant cost efficiencies that have been built in, which will help spur uptake and increase accessibility to WELL for more market sectors.”

In Europe, WELL has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. Nearly 200 projects across 14 countries are engaged with WELL, representing a quarter of global WELL project square footage. The strong growth of WELL over the past year has been led by early adopter markets, notably France, United Kingdom, Spain and the Netherlands – as well as rapid new expansion in Poland, Sweden and Ireland. Finland, Germany, Hungary, Italy and Norway have registered their first projects, and the Czech Republic and Slovakia markets are being driven by strong local industry leaders.

“With these changes, WELL v2 sharpens our ability to drive far-reaching change to buildings and communities in ways that help people thrive,” said Fedrizzi. “We’re looking forward to the market’s feedback as we move through this pilot phase.”

For more information about WELL v2, visit us at https://v2.wellcertified.com.

About IWBI

The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings and communities in ways that help people thrive. The WELL v2 pilot is a recently launched version of its popular WELL Building Standard, which will continue to be offered to the market, and the WELL Community Standard pilot, a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI convenes and mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere.

ADDENDUM – Europe:

Virginie Scaglia at HRO France, said: “WELL Certification provides an excellent platform to communicate our commitment to providing a healthy workplace and upholding the highest environmental standards in building design, construction and operations. As we began our journey, we knew we wanted SCENEO to be at the forefront of cutting-edge building science and technology. WELL Certification has helped us to gain a competitive edge in Paris’s real estate market, highlight our leadership in the sustainability movement, and, most importantly, improve the health and well-being of tenants and employees. WELL was a natural fit for us.”

“When we moved to our new workplace in central London, we were determined that the experience for our staff would be markedly different from before. We used WELL as part of a broader strategy to create an environment that promotes health, facilitates physical activity and increases collaboration. What emerged was an organisational transformation that has helped to improve employee satisfaction and productivity and deliver on our sustainability commitments. As a result, our Landsec workplace is the first commercial office in the world to achieve both WELL Certified Silver and BREEAM Outstanding, setting a global benchmark for healthy, sustainable office space,” said Ed Dixon, Sustainability Insights Director, Landsec.

Chris Hiatt, Landid director, said: “As the first building in the UK to achieve WELL Core & Shell Certification, The Porter Building sets a new bar for the design and development of offices. The workspace will positively impact business performance, through staff retention and attraction, well-being and productivity and will meet the aspirations of the very best talent. Wellness has become an increasingly important part of workplace strategies in recent years, reflecting a wider cultural shift towards greater healthier lifestyles. We expect that in five years’ time all new office buildings will be seeking WELL Certification, in the same way that new buildings today are expected to adhere to the highest sustainability standards. Well-being will simply become part of the language of office design and we are very proud to be playing a leading role in that transformation.”

"Here in the Nordics we have the purest outdoor air and nature combined with an active lifestyle. However, we have shut the door on them indoors where we spend 22 hours a day. As the first WELL Certified office in the Nordics, we at Green Building Partners want to lead the way in the Nordics and show that it's important to design indoor spaces that are not only environmentally and energy-friendly but also human-friendly. The strength of the WELL Building Standard is that it's holistic. The concepts helped us to design an office and ways to work that comprehensively improve our employees' well-being, creativity and productivity," said Konsta Tuokko, Senior Consultant at Green Building Partners.

Contact information

IWBI (Europe)
Kristen Coco, +44 (0) 7377 815 047
kristen.coco@wellcertified.com
or
IWBI (North America)
Callie Stanton, 646-654-3438
cstanton@nikecomm.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme